Multivariate analyses for predictors of PFS and OS in patients receiving BsAbs for MM
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| PFS multivariable analysis | |||
| Frailty | 1.7 | 0.54-12 | .58 |
| Age ≥70 years | 1.6 | 0.49-5 | .45 |
| ECOG ≥2 | 2.3 | 0.38-14 | .36 |
| CCI ≥2 | 1.2 | 0.23-6.6 | .8 |
| CrCl ≤60 | 0.88 | 0.19-4 | .87 |
| EMD | 1.1 | 0.38-3.1 | .88 |
| High-risk cytogenetics | 1 | 0.44-2.4 | .95 |
| Triple-class refractory disease | 0.49 | 0.15-1.6 | .24 |
| Grade ≥3 cytopenia <30 days, n (%) | 1.4 | 0.53-3.7 | .5 |
| Grade ≥3 infection <90 days, n (%) | 1.9 | 0.8-4.7 | .14 |
| Prior lines of therapy ≥4 | 2.4 | 0.49-12 | .28 |
| Prior anti-BCMA therapy | 1.3 | 0.53-3.2 | .55 |
| OS multivariable analysis | |||
| Frailty | 1.1 | 0.12-11 | .92 |
| Age ≥70 years | 3.5 | 0.75-17 | .11 |
| ECOG ≥2 | 4.6 | 0.41-51 | .22 |
| CCI ≥2 | 0.34 | 0.046-2.5 | .29 |
| CrCl ≤60 | 1.2 | 0.18-7.5 | .88 |
| EMD | 1.4 | 0.36-5.8 | .6 |
| High-risk cytogenetics | 1.6 | 0.42-6 | .48 |
| Triple-class refractory disease | 0.65 | 0.11-3.8 | .63 |
| Grade ≥3 cytopenia <30 days, n (%) | 2 | 0.49-7.8 | .34 |
| Grade ≥3 infection <90 days, n (%) | 1.8 | 0.52-6.5 | .34 |
| Prior lines of therapy ≥4 | 1.5 | 0.14-16 | .74 |
| Prior anti-BCMA therapy | 2 | 0.58-6.9 | .27 |
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| PFS multivariable analysis | |||
| Frailty | 1.7 | 0.54-12 | .58 |
| Age ≥70 years | 1.6 | 0.49-5 | .45 |
| ECOG ≥2 | 2.3 | 0.38-14 | .36 |
| CCI ≥2 | 1.2 | 0.23-6.6 | .8 |
| CrCl ≤60 | 0.88 | 0.19-4 | .87 |
| EMD | 1.1 | 0.38-3.1 | .88 |
| High-risk cytogenetics | 1 | 0.44-2.4 | .95 |
| Triple-class refractory disease | 0.49 | 0.15-1.6 | .24 |
| Grade ≥3 cytopenia <30 days, n (%) | 1.4 | 0.53-3.7 | .5 |
| Grade ≥3 infection <90 days, n (%) | 1.9 | 0.8-4.7 | .14 |
| Prior lines of therapy ≥4 | 2.4 | 0.49-12 | .28 |
| Prior anti-BCMA therapy | 1.3 | 0.53-3.2 | .55 |
| OS multivariable analysis | |||
| Frailty | 1.1 | 0.12-11 | .92 |
| Age ≥70 years | 3.5 | 0.75-17 | .11 |
| ECOG ≥2 | 4.6 | 0.41-51 | .22 |
| CCI ≥2 | 0.34 | 0.046-2.5 | .29 |
| CrCl ≤60 | 1.2 | 0.18-7.5 | .88 |
| EMD | 1.4 | 0.36-5.8 | .6 |
| High-risk cytogenetics | 1.6 | 0.42-6 | .48 |
| Triple-class refractory disease | 0.65 | 0.11-3.8 | .63 |
| Grade ≥3 cytopenia <30 days, n (%) | 2 | 0.49-7.8 | .34 |
| Grade ≥3 infection <90 days, n (%) | 1.8 | 0.52-6.5 | .34 |
| Prior lines of therapy ≥4 | 1.5 | 0.14-16 | .74 |
| Prior anti-BCMA therapy | 2 | 0.58-6.9 | .27 |
CrCl, creatinine clearance; EMD, extramedullary disease.